NCT03534934

Brief Summary

The goal of this translational study is to establish a newly emerging CT-based tool for the characterization of changes in bone micro-architecture and assessment of their implications for fracture-risk in a population of COPD patients at risk for osteoporosis. The tool will be suitable and generalizable across emerging CT scanners from different vendors, and it will provide a more structurally-based assessment of osteoporosis and bone loss than is provided by simple bone density measures. The study will characterize the impact of different COPD-related factors on bone structure, and their implications for fracture-risk, leading to the development of a COPD-specific model for assessment of fracture-risk that will utilize patient-specific demographic, clinical and radiographic data, and CT BMD at the spine, as well as bone structural measures at the hip and/or ankle.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
560

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Feb 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 16, 2018

Completed
1 month until next milestone

First Posted

Study publicly available on registry

May 23, 2018

Completed
9 months until next milestone

Study Start

First participant enrolled

February 26, 2019

Completed
6.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 19, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 19, 2025

Completed
Last Updated

January 28, 2026

Status Verified

January 1, 2026

Enrollment Period

6.1 years

First QC Date

April 16, 2018

Last Update Submit

January 7, 2026

Conditions

Keywords

COPDOsteoporosis

Outcome Measures

Primary Outcomes (3)

  • Prevalent vertebral fractures at baseline

    Method: Prevalent fracture cases at the baseline visit will be determined using expert visual reading of the baseline lateral spine CT scout scan.

    Baseline Visit

  • CT-based fracture-risk

    Method: Fragility fracture-risk will be computed using a CT-based model comprising of patient-specific demographic, clinical and radiographic data, CT bone mineral density at the spine, and CT bone micro-structural measures at the ankle.

    Baseline Visit

  • DXA-based fracture risk

    Method: Fragility fracture-risk will be computed using a DXA-based model comprising of patient-specific demographic, clinical and radiographic data, and whole-body, spine, and hip DXA bone mineral density.

    Baseline Visit

Secondary Outcomes (2)

  • CT bone mineral density at the spine

    Change from baseline and three year follow up visit

  • DXA Bone Mineral Density

    Change from baseline and three year follow up visit.

Study Arms (2)

Baseline

EXPERIMENTAL

Smokers, defined has having at least a 10 pack-year lifetime history, with and without COPD will participate in the following interventions: Vital Signs Urine Pregnancy Test on woman of child bearing potential Pre- and Post-Bronchodilator Spirometry Questionnaires Blood Test for Vitamin D level, Hemoglobin A1c, and creatinine level Duel-energy X-ray absorptiometry scan (DXA) of the whole body, spine, and hip Duel-energy X-ray absorptiometry scan (DXA) for vertebral fracture assessment Multi-detector computed tomography (MDCT) of the hip and ankle

Diagnostic Test: Vital signsDiagnostic Test: Urine Pregnancy TestOther: QuestionnairesDiagnostic Test: Blood TestDiagnostic Test: Duel-energy X-ray absorptiometry scanDiagnostic Test: Multi-detector computed tomographyDiagnostic Test: Dual-energy X-ray absorptiometry scan

3 year follow-up

EXPERIMENTAL

All subjects who completed a baseline visit will return for a follow-up visit and participate in the following interventions: Vital Signs Urine Pregnancy Test on woman of child bearing potential Pre- and Post-Bronchodilator Spirometry Questionnaires Blood Test for Vitamin D level, Hemoglobin A1c, and creatinine level Duel-energy X-ray absorptiometry scan (DXA) of the whole body, spine, and hip Duel-energy X-ray absorptiometry scan (DXA) for vertebral fracture assessment Multi-detector computed tomography (MDCT) of the hip and ankle

Diagnostic Test: Vital signsDiagnostic Test: Urine Pregnancy TestOther: QuestionnairesDiagnostic Test: Blood TestDiagnostic Test: Duel-energy X-ray absorptiometry scanDiagnostic Test: Multi-detector computed tomographyDiagnostic Test: Dual-energy X-ray absorptiometry scan

Interventions

Vital signsDIAGNOSTIC_TEST

Heart rate, respirations, blood pressure, temperature, oxygen saturation arterial oxygen saturation (SaO2), height and weight

3 year follow-upBaseline
Urine Pregnancy TestDIAGNOSTIC_TEST

Urine pregnancy test done on woman of childbearing potential.

3 year follow-upBaseline

Subject Questionnaire Calcium Intake Questionnaire Home and Work Activities Survey

3 year follow-upBaseline
Blood TestDIAGNOSTIC_TEST

Blood test for vitamin D level, Hemoglobin A1c, and creatinine level

3 year follow-upBaseline

Bone density measurement

Also known as: DXA scan
3 year follow-upBaseline

Hip and ankle CT scan

Also known as: MDCT, CT scan
3 year follow-upBaseline

Vertebral fracture assessment

Also known as: DXA scan
3 year follow-upBaseline

Eligibility Criteria

Age45 Years - 90 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Current or former smoker, defined as having at least 10-pack year lifetime history
  • Age: 45-90
  • Subjects will be stratified into groups based on COPD disease status: smokers with COPD and smokers without COPD.
  • Smokers with COPD will be further stratified into three groups: low emphysema (\< 3%), moderate emphysema (between 3 and 10%), and severe emphysema (\> 10%).

You may not qualify if:

  • Pregnant or breast-feeding
  • Metastatic Malignancy
  • Currently receiving dialysis
  • Any lower extremity fracture within the last year
  • Any lower extremity fracture with hardware implant(s)
  • History of bilateral tibia fractures

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

University of Iowa Hospitals and Clinics

Iowa City, Iowa, 52242, United States

Location

Columbia University Medical Center

New York, New York, 10032, United States

Location

MeSH Terms

Conditions

Pulmonary Disease, Chronic ObstructiveOsteoporosis

Interventions

Vital SignsSurveys and QuestionnairesHematologic TestsAbsorptiometry, PhotonMultidetector Computed TomographyTomography, X-Ray Computed

Condition Hierarchy (Ancestors)

Lung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsBone Diseases, MetabolicBone DiseasesMusculoskeletal DiseasesMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Physical ExaminationDiagnostic Techniques and ProceduresDiagnosisData CollectionEpidemiologic MethodsInvestigative TechniquesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public HealthClinical Laboratory TechniquesRadiographyDiagnostic ImagingDensitometryPhotometryChemistry Techniques, AnalyticalTomography, Spiral ComputedImage Interpretation, Computer-AssistedRadiographic Image EnhancementImage EnhancementPhotographyTomography, X-RayTomography

Study Officials

  • Punam Saha, PhD

    University of Iowa

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SEQUENTIAL
Model Details: All subjects will participate in both baseline and three year follow-up visits and undergo identical interventions.
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

April 16, 2018

First Posted

May 23, 2018

Study Start

February 26, 2019

Primary Completion

March 19, 2025

Study Completion

March 19, 2025

Last Updated

January 28, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will share

Clinical exam, questionnaire, and image-derived data will be made available to other researchers who request it formally. The data will be de-identified and linked only by code numbers. To further minimize the risk of breaches of confidentiality, we will establish data-use sharing agreements, and consider employment of electronic firewalls, locked storage facilities, password authentication of users, audit trails, and disaster prevention/recovery plans. We will stipulate that data are used only for research purposes, that proposed research using the data will be reviewed by an Institutional Review Board, and data will not be transferred to other users. The data would be available upon completion of necessary data management and statistical analyses. At that time, data could be provided on appropriate storage media via mail. Data files would be provided in SAS format, with PDF documentation files. We also will provide copies of questionnaires and images from which our data are derived.

Time Frame
The data would be available about 12 months after completion of the grant, with necessary data management and statistical analyses done by then. At that time, data could be provided on the appropriate storage media through the mail, with appropriate variable labels and other necessary documentation.
Access Criteria
Data will only be available to researchers who formally request it and who have entered into a data-use agreement with the principal investigators.

Locations